TABLE 1.
Week 1 | Week 2 | Week 4 | Week 6 | |
Dates of data collection | 18–24 March | 25–27 March | 8–10 April | 29 April to 4 May |
Number of evaluable respondents | 59 | 55 | 61 | 63 |
For ongoing trials, the % of clinics allowing: | ||||
Patients to attend onsite trial visits | 71% | 60% | 57% | 74.6% |
New enrolment into ongoing trials | 22% | 15% | NA | NA |
Onsite clinical research associate monitoring visits | 16% | 11% | NA | NA |
Study drug to be shipped to patients | 55% | 66% | 67% | 65.1% |
New trials | ||||
Trial set-up activities to continue | 57% | 60% | 52% | 71.4% |
Site initiation visits | 5% | 14% | NA | NA |
Initiation of CFTR modulator extension open-label studies | 91% | 78% | NA | NA |
The % of clinics who received guidance from: | ||||
Hospital | 55% | 68% | NA | NA |
Ethics committee | 34% | 23% | NA | NA |
National competent authority | 20% | 32% | NA | NA |
Sponsor | 88% | 90% | 97% | 93.7% |
CFTR: cystic fibrosis transmembrane conductance regulator; NA: question not asked.